Results 81 to 90 of about 6,111 (204)

TARGET: Do Tirofiban And ReoPro Give Similar Efficacy Trial? [PDF]

, 2000
Eric J. Topol
openalex   +1 more source

There is no difference in safety and efficacy mechanical thrombectomy alone or mechanical thrombectomy with tirofiban for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis

Interdisciplinary Neurosurgery, 2022
Background: Mechanical thrombectomy (MT) is a widely proven method to treat acute ischemic stroke (AIS) during mechanical thrombectomy and acute stenting and angioplasty is a topic discussed till this day regarding safety and efficacy.
Hari Movva, Rani Rabah, Wondwossen Tekle, Laurie Preston, Hari Kotta, Ameer E Hassan   +5 more
doaj  

Anticoagulation during Cardiopulmonary Bypass in Patients with Heparin-induced Thrombocytopenia Type II and Renal Impairment Using Heparin and the Platelet Glycoprotein IIb–IIIa Antagonist Tirofiban [PDF]

, 2001
Andreas Koster, Marian Kukucka, Friedhelm Bach, Oliver Meyer, Thomas Fischer, F. Mertzlufft, Matthias Loebe, Roland Hetzer, Hermann Kuppe   +8 more
openalex   +1 more source

Consensus interpretation on "Expert consensus on clinical application of tirofiban in atherosclerotic cerebrovascular disease"

Chinese Journal of Contemporary Neurology and Neurosurgery, 2020
Platelet glycoprotein (GP) Ⅱ b/Ⅲ a receptor is the final common pathway of platelet aggregation and thrombosis, which can specifically and rapidly inhibit platelet aggregation. In recent years, more and more evidences support that tirofiban, a GP Ⅱ b/Ⅲ a
Xiao⁃chuan HUO, Zhong⁃rong MIAO
doaj  

Low-dose intravenous tirofiban infusion after endovascular recanalization for non-acute middle cerebral artery occlusion

Heliyon, 2022
Background and purpose: Endovascular recanalization for patients with symptomatic non-acute middle cerebral artery occlusion still remines challenging. Postoperative treatment is still controversial.
Zhang Xi, Chen Zhibin, Luo Yun, Duan Guangxin, Zhang He, Li Jingwei, Xu Yun   +6 more
doaj  

Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function [PDF]

, 2001
Eli I. Lev, Julio Osende, Merwin Richard, Jonathan A. Robbins, Jenny A. Delfin, O Rodríguez, Sanjeev Sharma, Tim Jayasundera, Juan J. Badimón, Jonathan D. Marmur   +9 more
openalex   +1 more source

Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects [PDF]

, 2001
Ute Klinkhardt, Jochen Graff, Dagmar Westrup, C.M. Kirchmaier, Hans‐Ulrich Esslinger, H.K. Breddin, Sebastian Harder   +6 more
openalex   +1 more source

Eptifibatide and 7E3, but Not Tirofiban, Inhibit α _v β ₃ Integrin–Mediated Binding of Smooth Muscle Cells to Thrombospondin and Prothrombin [PDF]

, 2001
Manjiri Lele, Mansoor Sajid, Nadeem Wajih, George A. Stouffer   +3 more
openalex   +1 more source

Effects of tirofiban on large vessel occlusion stroke are modified by etiology and renal function

Annals of Clinical and Translational Neurology
Objective Renal function can modify the outcomes of large vessel occlusion (LVO) stroke across stroke etiologies in disparate degrees. The presence of renal function deficit can also impair the pharmacokinetics of tirofiban.
Chang Liu, Fengli Li, Liyuan Chen, Jiacheng Huang, Hongfei Sang, Thanh N. Nguyen, Jeffrey L. Saver, Mohamad Abdalkader, Weiling Kong, Jie Yang, Changwei Guo, Chen Gong, Liping Huang, Yanzhu Pan, Xinxin Wang, Yangmei Chen, Zhongming Qiu, Wenjie Zi   +17 more
doaj   +1 more source

Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban [PDF]

, 2001
Christopher P. Cannon, William S. Weintraub, Laura A. Demopoulos, Ralph Vicari, Martin J. Frey, Nasser Lakkis, Franz‐Josef Neumann, Debbie Robertson, Paul DeLucca, Peter M. DiBattiste, C. Michael Gibson, Eugene Braunwald   +11 more
openalex   +1 more source